Advertisement

Comparison of Therapeutic Potential of Cytokines

  • James E. Talmadge
  • Paul L. Black

Abstract

Biological response modifiers (BRMs) are those agents or approaches that influence the relationship between the tumor and host by modifying the hosts response to tumor cells, with resultant therapeutic activity (9). A series of studies with recombinant cytokines designed to better understand their immunomodulatory and therapeutic properties have been undertaken. The present report discusses recombinant murine interferon-gamma (rM IFN-g), recombinant human tumor necrosis factor (rH TNF), rH interleukin-2 (rH IL-2), and rM colony stimulating factor-gm (rM CSF-gm). We discuss the development of Optimal Therapeutic Protocols (OTP) for preclinical studies and initial clinical trials that have been initiated to test the resultant clinical hypotheses.

Keywords

Maximum Tolerate Dose Therapeutic Activity Hairy Cell Leukemia Biological Response Modifier Effector Cell Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P. L. Black, H. Phillips, H. Tribble, R. Pennington, M. Schneider, and J. E. Talmadge, Immune responses in tumor-bearing organs and therapeutic activity of rM IFN-G, Fed. Proc. 46: 1499 (1987).Google Scholar
  2. 2.
    M. A. Cheever and P. D. Greenberg, In vivo administration of interleukin-2, Contemp. Top. Mol. Immunol. 10: 263–282 (1985).PubMedGoogle Scholar
  3. 3.
    M. A. Cheever, J. A. Thompson, D. J. Peace, and P. D. Greenberg, Potential uses of interleukin 2 in cancer therapy, Immunobiology. 172: 365–382 (1986).PubMedCrossRefGoogle Scholar
  4. 4.
    B. S. Edwards, J. A. Merritt, R. C. Fuhlbrigge, and E. C. Borden, Low doses of interferon alpha result in more effective clinical natural killer cell activation, J. Clin. Invest. 75: 1908 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    M. S. Ernstoff, S. Reich, Y. Nishoda, and J. M. Kirkwood, Immunological assessment of melanoma patients treated with recombinant interferon gamma (rIFN-gamma, Biogen, Inc., Cambridge, MA) in a phase I/II trial, Proc. M. Assoc. Cancer Res. 26: 280 (1985).Google Scholar
  6. 6.
    D. Hartmann, J. S. Adams, A. K. Meeker, M. A. Schneider, B. F. Lenz, and J. E. Talmadge, Dissociation of therapeutic and toxic effects of polyinosinic-polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethyl cellulose in tumor-bearing mice. Cancer Res. 46: 1331–1338 (1986).PubMedGoogle Scholar
  7. 7.
    E. S. Kleinerman, R. Kurzrock, D. Wyatt, J. R. Quesada, J. U. Gutterman, and I. J. Fidler, Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Cancer Res. 46: 5401–5405 (1986).PubMedGoogle Scholar
  8. 8.
    A. E. Maluish, W. J. Urba, K. Gordon, W. R. Overton, D. Coggin, E. R. Crisp, R. Williams, and S. A. Sherwin, Determination of an optimum biological response modifying (BRM) dose of interferon gamma in melanoma patients, Proc. Am. Soc. Clin. Oncol. in press (1987).Google Scholar
  9. 9.
    E. Mihich and A. Fefer, Biological response modifiers subcommittee report, in: “National Cancer Institute Monograph63:1–278 (1983).Google Scholar
  10. 10.
    S. A. Rosenberg, M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, and J. M. Skibber, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Eng. J. Med. 313: 1485–1492 (1985).CrossRefGoogle Scholar
  11. 11.
    S. A. Rosenberg, P. Spiess, and R. Lafreniere, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1322 (1986).PubMedCrossRefGoogle Scholar
  12. 12.
    J. E. Talmadge and R. B. Herberman. The preclinical screening laboratory: Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat. Rep. 70: 171–182 (1986).PubMedGoogle Scholar
  13. 13.
    J. E. Talmadge, H. Phillips, J. Schindler, H. Tribble, and R. Pennington, A systematic preclinical study on the therapeutic properties of rH IL-2 for the treatment of metastatic disease. Cancer Res, in press (1987).Google Scholar
  14. 14.
    J. E. Talmadge, H. R. Tribble, R. W. Pennington, H. Phillips, and R. H. Wiltrout, Immunomodulatory and immunotherapeutic properties of recombinant gamma interferon and recombinant tumor necrosis factor in mice. Cancer Res, in press (1987).Google Scholar
  15. 15.
    W. H. West, K. W. Tauer, J. R. Yarnelli, G. L. Marshall, D. W. Orr, G. B. Thurman, and R. K. Oldham, Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer, Biol. Ther. Cancer A 1986 Update.Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • James E. Talmadge
    • 1
  • Paul L. Black
    • 1
  1. 1.National Cancer Institute-Frederick Cancer Research FacilityPreclinical Screening Laboratory, Program Resources, Inc.FrederickUSA

Personalised recommendations